{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T14:48:52Z","timestamp":1791902932898,"version":"4.3.4"},"reference-count":34,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T00:00:00Z","timestamp":1791849600000},"content-version":"vor","delay-in-days":12,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"funder":[{"DOI":"10.13039\/100004331","name":"Johnson and Johnson","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004331","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Pulm. circ."],"published-print":{"date-parts":[[2026,10]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:p>\n                    Selexipag is an oral prostacyclin receptor agonist approved for pulmonary arterial hypertension (PAH). This single\u2010center, retrospective study described oral selexipag dosing patterns and persistence, overall and stratified by history of methamphetamine (meth) use, at an expert center in California, USA, using a multidisciplinary, nurse\u2010directed protocol entailing frequent follow\u2010up and individualized side effect management. Medical charts of patients with PAH initiating oral selexipag between January 2016 and March 2023 were abstracted. Patient characteristics and dosing patterns were described up to 14 months post\u2010initiation. The individualized maintenance dose (IMD) was the first dose maintained for \u2265\u200914 days after reaching the maximum tolerated dose. Persistence was described using Kaplan\u2013Meier analysis. A total of 200 patients initiated oral selexipag (median age 52 years; 69.5% female; 54.5% White; 70.5% on triple therapy; 41% with a history of meth use). Most patients (89.0%) achieved maintenance (median IMD: 900\u2009\u03bcg twice daily; median time to maintenance: 2.5 months). Selexipag persistence at 1 year was 76.2%, with most discontinuations occurring within 2 months of initiation. Similar proportions of patients with and without a history of meth use achieved maintenance (85.4% vs. 91.5%;\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.3) and persisted on selexipag at 1 year (74.0% vs. 77.5%;\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.9). Using a multidisciplinary nurse\u2010directed protocol, most patients with PAH were titrated to their IMD and persisted on oral selexipag, including those with a history of meth use. These findings highlight the importance of frequent patient contact for dose adjustment and side effect management, particularly earlier in the titration process.\n                  <\/jats:p>","DOI":"10.1002\/pul2.70384","type":"journal-article","created":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T14:22:49Z","timestamp":1791901369000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["A Team\u2010Based Patient Engagement Approach to Selexipag Initiation and Maintenance in Pulmonary Arterial Hypertension (TEAM PAH): Real\u2010World Dosing Patterns and Persistence Among Patients With and Without a History of Methamphetamine Use"],"prefix":"10.1002","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3762-7918","authenticated-orcid":false,"given":"Samuel B.","family":"Brusca","sequence":"first","affiliation":[{"name":"Division of Cardiology University of California San Francisco San Francisco California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amanda Schnell","family":"Heringer","sequence":"additional","affiliation":[{"name":"Division of Cardiology University of California San Francisco San Francisco California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark Joshua","family":"Lacsamana","sequence":"additional","affiliation":[{"name":"Division of Cardiology University of California San Francisco San Francisco California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-8930-341X","authenticated-orcid":false,"given":"Anya","family":"Thakur","sequence":"additional","affiliation":[{"name":"Division of Cardiology University of California San Francisco San Francisco California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"Thomas","sequence":"additional","affiliation":[{"name":"Division of Cardiology University of California San Francisco San Francisco California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-4057-0540","authenticated-orcid":false,"given":"Christina","family":"Benninger","sequence":"additional","affiliation":[{"name":"Johnson &amp; Johnson Titusville New Jersey USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gurinderpal","family":"Doad","sequence":"additional","affiliation":[{"name":"Johnson &amp; Johnson Titusville New Jersey USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-4267-1918","authenticated-orcid":false,"given":"Paul","family":"Strachan","sequence":"additional","affiliation":[{"name":"Johnson &amp; Johnson Titusville New Jersey USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Walden","sequence":"additional","affiliation":[{"name":"Johnson &amp; Johnson Titusville New Jersey USA"},{"name":"Mineralys Therapeutics Radnor Pennsylvania USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9874-0522","authenticated-orcid":false,"given":"Ambika","family":"Satija","sequence":"additional","affiliation":[{"name":"Analysis Group Inc. Boston Massachusetts USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gayatri","family":"Marathe","sequence":"additional","affiliation":[{"name":"Analysis Group Inc. Toronto Ontario Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henrietta","family":"Blinder","sequence":"additional","affiliation":[{"name":"Analysis Group Inc. Montr\u00e9al Quebec Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9439-595X","authenticated-orcid":false,"given":"Marjolaine","family":"Gauthier\u2010Loiselle","sequence":"additional","affiliation":[{"name":"Analysis Group Inc. Montr\u00e9al Quebec Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0183-4704","authenticated-orcid":false,"given":"Teresa","family":"De Marco","sequence":"additional","affiliation":[{"name":"Division of Cardiology University of California San Francisco San Francisco California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,10,13]]},"reference":[{"issue":"14","key":"e_1_2_12_2_1","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1001\/jama.2022.4402","article-title":"Diagnosis and Treatment of Pulmonary Arterial Hypertension: A Review","volume":"327","author":"Ruopp N. F.","year":"2022","journal-title":"Journal of the American Medical Association"},{"issue":"3","key":"e_1_2_12_3_1","first-page":"53","article-title":"Reducing Economic Burden and Improving Quality of Life in Pulmonary Arterial Hypertension","volume":"27","author":"Burgoyne D. S.","year":"2021","journal-title":"American Journal of Managed Care"},{"issue":"1","key":"e_1_2_12_4_1","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1007\/s41669-023-00453-8","article-title":"Economic Burden of Delayed Diagnosis in Patients With Pulmonary Arterial Hypertension (PAH)","volume":"8","author":"DuBrock H. M.","year":"2024","journal-title":"PharmacoEconomics \u2010 Open"},{"issue":"8","key":"e_1_2_12_5_1","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1111\/resp.13768","article-title":"Diagnostic Delay in Pulmonary Arterial Hypertension: Insights From the Australian and New Zealand Pulmonary Hypertension Registry","volume":"25","author":"Khou V.","year":"2020","journal-title":"Respirology"},{"issue":"3","key":"e_1_2_12_6_1","doi-asserted-by":"crossref","first-page":"s3","DOI":"10.18553\/jmcp.2016.22.3-a.s3","article-title":"New Therapeutic Paradigms and Guidelines in the Management of Pulmonary Arterial Hypertension","volume":"22","author":"Hill N. S.","year":"2016","journal-title":"Journal of Managed Care and Specialty Pharmacy"},{"issue":"9","key":"e_1_2_12_7_1","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.121.024969","article-title":"Mortality in Pulmonary Arterial Hypertension in the Modern Era: Early Insights From the Pulmonary Hypertension Association Registry","volume":"11","author":"Chang K. Y.","year":"2022","journal-title":"Journal of the American Heart Association"},{"issue":"12","key":"e_1_2_12_8_1","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1164\/rccm.202012-4317SO","article-title":"Pulmonary Arterial Hypertension: Diagnosis, Treatment, and Novel Advances","volume":"203","author":"Maron B. A.","year":"2021","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"issue":"13","key":"e_1_2_12_9_1","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1161\/CIRCULATIONAHA.104.503540","article-title":"Pulmonary Arterial Hypertension","volume":"114","author":"McLaughlin V. V.","year":"2006","journal-title":"Circulation"},{"key":"e_1_2_12_10_1","doi-asserted-by":"crossref","DOI":"10.3389\/fcvm.2024.1445193","article-title":"Trends and Patterns in Pulmonary Arterial Hypertension\u2010Associated Hospital Admissions Among Methamphetamine Users: A Decade\u2010Long Study","volume":"11","author":"Husein A.","year":"2024","journal-title":"Frontiers in Cardiovascular Medicine"},{"key":"e_1_2_12_11_1","unstructured":"US Drug Enforcement Administration. \u201cNational Drug Threat Assessment.\u201d2024."},{"issue":"6","key":"e_1_2_12_12_1","doi-asserted-by":"crossref","first-page":"1518","DOI":"10.1016\/j.chest.2024.01.014","article-title":"Overview of Methamphetamine\u2010Associated Pulmonary Arterial Hypertension","volume":"165","author":"Charoenpong P.","year":"2024","journal-title":"Chest"},{"issue":"4","key":"e_1_2_12_13_1","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1513\/AnnalsATS.202007-774OC","article-title":"Clinical Differences and Outcomes Between Methamphetamine\u2010Associated and Idiopathic Pulmonary Arterial Hypertension in the Pulmonary Hypertension Association Registry","volume":"18","author":"Kolaitis N. A.","year":"2021","journal-title":"Annals of the American Thoracic Society"},{"issue":"6","key":"e_1_2_12_14_1","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1164\/rccm.201705-0943OC","article-title":"Features and Outcomes of Methamphetamine\u2010Associated Pulmonary Arterial Hypertension","volume":"197","author":"Zamanian R. T.","year":"2018","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"issue":"1","key":"e_1_2_12_15_1","doi-asserted-by":"crossref","DOI":"10.1002\/pul2.70242","article-title":"Methamphetamine\u2010Associated Pulmonary Arterial Hypertension: Impact, Mechanisms, and a Framework for Management","volume":"16","author":"Sood N.","year":"2026","journal-title":"Pulmonary Circulation"},{"issue":"26","key":"e_1_2_12_16_1","doi-asserted-by":"crossref","first-page":"2522","DOI":"10.1056\/NEJMoa1503184","article-title":"Selexipag for the Treatment of Pulmonary Arterial Hypertension","volume":"373","author":"Sitbon O.","year":"2015","journal-title":"New England Journal of Medicine"},{"key":"e_1_2_12_17_1","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1016\/j.healun.2025.11.007","article-title":"Evaluating Oral Selexipag in PAH: Insights on Survival, Safety and Dosing Patterns From the Complete Observation Period of GRIPHON and Its Open\u2010Label Extension","volume":"45","author":"McLaughlin V. V.","year":"2025","journal-title":"Journal of Heart and Lung Transplantation"},{"key":"e_1_2_12_18_1","unstructured":"UPTRAVI\u00ae (selexipag) prescribing information. \u201cActelion Pharmaceuticals Inc.\u201d2022[cited 2025 June 26] https:\/\/www.janssenlabels.com\/package-insert\/product-monograph\/prescribing-information\/UPTRAVI-pi.pdf."},{"issue":"3","key":"e_1_2_12_19_1","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1177\/2045893217719250","article-title":"Management of Prostacyclin Side Effects in Adult Patients With Pulmonary Arterial Hypertension","volume":"7","author":"Kingman M.","year":"2017","journal-title":"Pulmonary Circulation"},{"issue":"1","key":"e_1_2_12_20_1","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1007\/s41030-017-0039-1","article-title":"Collaborative Care: A Defining Characteristic for a Pulmonary Hypertension Center","volume":"3","author":"Stewart T.","year":"2017","journal-title":"Pulmonary Therapy"},{"issue":"2","key":"e_1_2_12_21_1","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/j.healun.2023.09.016","article-title":"Disease Characteristics, Treatments, and Outcomes of Patients With Pulmonary Arterial Hypertension Treated With Selexipag in Real\u2010World Settings From the SPHERE Registry (SelexiPag: tHe usErs dRug Registry)","volume":"43","author":"McLaughlin V.","year":"2024","journal-title":"Journal of Heart and Lung Transplantation"},{"issue":"4","key":"e_1_2_12_22_1","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/j.healun.2021.01.006","article-title":"Patient and Disease Characteristics of the First 500 Patients With Pulmonary Arterial Hypertension Treated With Selexipag in Real\u2010World Settings From SPHERE","volume":"40","author":"Kim N. H.","year":"2021","journal-title":"Journal of Heart and Lung Transplantation"},{"issue":"3","key":"e_1_2_12_23_1","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1007\/s12325-023-02730-8","article-title":"Real\u2010World Management of Patients With Pulmonary Arterial Hypertension: Insights From EXPOSURE","volume":"41","author":"Muller A.","year":"2024","journal-title":"Advances in Therapy"},{"issue":"9","key":"e_1_2_12_24_1","doi-asserted-by":"crossref","first-page":"3645","DOI":"10.1007\/s12325-024-02946-2","article-title":"Four\u2010Strata Risk Assessment in Patients With Pulmonary Arterial Hypertension Treated With Selexipag in Real\u2010World Settings (EXPOSURE Study)","volume":"41","author":"Lange T. J.","year":"2024","journal-title":"Advances in Therapy"},{"issue":"1","key":"e_1_2_12_25_1","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/j.chest.2020.08.2069","article-title":"Development and Validation of An Abridged Version of the REVEAL 2.0 Risk Score Calculator, REVEAL Lite 2, for Use in Patients With Pulmonary Arterial Hypertension","volume":"159","author":"Benza R. L.","year":"2021","journal-title":"Chest"},{"issue":"1","key":"e_1_2_12_26_1","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1007\/s12325-021-01898-1","article-title":"Long\u2010Term Survival, Safety and Tolerability With Selexipag in Patients With Pulmonary Arterial Hypertension: Results From GRIPHON and Its Open\u2010Label Extension","volume":"39","author":"Gali\u00e8 N.","year":"2022","journal-title":"Advances in Therapy"},{"issue":"1","key":"e_1_2_12_27_1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1177\/2045894019832199","article-title":"Real\u2010Life Data on Selexipag for the Treatment of Pulmonary Hypertension","volume":"9","author":"Barnikel M.","year":"2019","journal-title":"Pulmonary Circulation"},{"issue":"11","key":"e_1_2_12_28_1","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1080\/14740338.2022.2069750","article-title":"Real\u2010World Practice Patterns and Characteristics of Adverse Events With Selexipag in Korean Patients With Pulmonary Arterial Hypertension","volume":"21","author":"Chang S. A.","year":"2022","journal-title":"Expert Opinion on Drug Safety"},{"key":"e_1_2_12_29_1","doi-asserted-by":"crossref","DOI":"10.3389\/fcvm.2022.991586","article-title":"Selexipag\u2010Based Triple Combination Therapy Improves Prognosis in Chinese Pulmonary Arterial Hypertension Patients","volume":"9","author":"Cui X.","year":"2022","journal-title":"Frontiers in Cardiovascular Medicine"},{"issue":"3","key":"e_1_2_12_30_1","doi-asserted-by":"crossref","DOI":"10.1002\/pul2.12403","article-title":"Selexipag in Patients With Pulmonary Arterial Hypertension Associated With Connective Tissue Disease (PAH\u2010CTD): Real\u2010World Experience From EXPOSURE","volume":"14","author":"Gaine S.","year":"2024","journal-title":"Pulmonary Circulation"},{"issue":"10","key":"e_1_2_12_31_1","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0331008","article-title":"Start Up: A French Program to Support Patients With Pulmonary Arterial Hypertension During the Adjustment of Prostanoids to the Individualized Optimal Dose","volume":"20","author":"Bergot E.","year":"2025","journal-title":"PLoS One"},{"issue":"1","key":"e_1_2_12_32_1","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1002\/ame2.12347","article-title":"Comparing the Efficacy and Safety of Low, Medium, and High Dosages of Selexipag for Treating Pulmonary Hypertension: A Systematic Review and Meta\u2010Analysis","volume":"7","author":"Wang S.","year":"2024","journal-title":"Animal Models and Experimental Medicine"},{"issue":"1","key":"e_1_2_12_33_1","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1007\/s40801-025-00536-4","article-title":"Real\u2010World Experience With Selexipag in Patients With Pulmonary Arterial Hypertension: Treatment Patterns and Outcomes Across Baseline Risk Strata (SPHERE and EXPOSURE Studies)","volume":"13","author":"Escribano Subias P.","year":"2026","journal-title":"Drugs \u2010 Real World Outcomes"},{"key":"e_1_2_12_34_1","unstructured":"United Nations Office of Drugs and Crime (UNODC).Opiates and Methamphetamine Trafficking on the Balkan Route: Drug Flows Illicit Incomes and Illicit Financial Flows(United Nations 2025)."},{"key":"e_1_2_12_35_1","unstructured":"United Nations Office of Drugs and Crime (UNODC).Synthetic Drugs in East and Southeast Asia: Latest Developments and Challenges(United Nations 2024)."}],"container-title":["Pulmonary Circulation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/pul2.70384","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/pul2.70384","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/pul2.70384","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T14:23:02Z","timestamp":1791901382000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/pul2.70384"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":34,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["10.1002\/pul2.70384"],"URL":"https:\/\/doi.org\/10.1002\/pul2.70384","archive":["Portico"],"relation":{},"ISSN":["2045-8940","2045-8940"],"issn-type":[{"value":"2045-8940","type":"print"},{"value":"2045-8940","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"2026-01-15","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-08-06","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-10-13","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e70384"}}